文档下载 文档下载导航
设为首页 | 加入收藏
搜索 请输入内容:  
 导航当前位置: 文档下载 > 所有分类 > 医药卫生 > 临床医学 > 替米沙坦对急性卒中预后复发的作用
侵权投诉

替米沙坦对急性卒中预后复发的作用

EffectofTelmisartanonFunctionalOutcome,Recurrence,

andBloodPressureinPatientsWithAcuteMild

IschemicStroke

APRoFESSSubgroupAnalysis

PhilipM.W.Bath,MD,FRCP;Renee´H.Martin,PhD;YukoPalesch,PhD;DanielCotton,MS;SalimYusuf,MB,BS,DPhil;RalphSacco,MD;Hans-ChristophDiener,MD,PhD;DaniloToni,MD;

ConradoEstol,MD,PhD;RobinRoberts,MSc;forthePRoFESSStudyGroup

BackgroundandPurpose—Highbloodpressure(BP)iscommoninacuteischemicstrokeandassociatedindependentlywithapoorfunctionaloutcome.However,themanagementofBPacutelyremainsunclearbecausenolargetrialshavebeencompleted.

Methods—ThefactorialPRoFESSsecondarystrokepreventiontrialassessedBP-loweringandantiplateletstrategiesin20332patients;1360wereenrolledwithin72hoursofischemicstroke,withtelmisartan(angiotensinreceptorantagonist,80mg/d,n 647)vsplacebo(n 713).Forthisnonprespecifiedsubgroupanalysis,theprimaryoutcomewasfunctionaloutcomeat30days;secondaryoutcomesincludeddeath,recurrence,andhemodynamicmeasuresatupto90days.Analyseswereadjustedforbaselineprognosticvariablesandantiplateletassignment.

Results—Patientswererepresentativeofthewholetrial(age67years,male65%,baselineBP147/84mmHg,smallarterydisease60%,NIHSS3)andbaselinevariablesweresimilarbetweentreatmentgroups.Themeantimefromstroketorecruitmentwas58hours.Combineddeathordependency(modifiedRankinscale:OR,1.03;95%CI,0.84–1.26;P 0.81;death:OR,1.05;95%CI,0.27–4.04;andstrokerecurrence:OR,1.40;95%CI,0.68–2.89;P 0.36)didnotdifferbetweenthetreatmentgroups.Incomparisonwithplacebo,telmisartanloweredBP(141/82vs135/78mmHg,difference6to7mmHgand2to4mmHg;P 0.001),pulsepressure(3to4mmHg;P 0.002),andrate-pressureproduct(466mmHg.bpm;P 0.0004).Conclusion—Treatmentwithtelmisartanin1360patientswithacutemildischemicstrokeandmildlyelevatedBPappearedtobesafewithnoexcessinadverseevents,wasnotassociatedwithasignificanteffectonfunctionaldependency,death,orrecurrence,andmodestlyloweredBP.(Stroke.2009;40:3541-3546.)KeyWords:acutestrokeⅢbloodpressureⅢischemicstrokeⅢoutcomeⅢrandomizedcontrolledtrialⅢtelmisartan

ighbloodpressure(BP)ispresentin70%to80%ofpatientswithacuteischemicstroke6,7andisassociatedindependentlywithapooroutcome.7–10However,thereisareluctancetolowerahighBPbecauseischemicstrokeisassociatedwithfocalattenuationofcerebralautoregulation.Asaresult,thereisequipoiseinwhetherhighBPshouldbelowered(epidemiologicalevidence)ornot(pathophysiolog-icalconcerns).

PreviousdataontheeffectsofBPloweringonfunctionaloutcomeinacutestrokearesparseandhavegivenconflictingresults.Trialsofcalciumchannelblockerswereineffectiveoverall,11andsomestudiesreportedthentobehazardous.12,13The -receptorantagonistswereassociatedwithaworseoutcomein1trial.14TheACCESStrialfoundthattreatmentwithoralcandesartan(angiotensinreceptorantagonist[ARA])wasassociatedwithreducedrecurrentvascular

H

eventsat1year(secondaryoutcome)buthadnoeffectonfunctionaloutcomeat3months(primaryoutcome)orBPoverthecourseofthefirst7daysoftreatment.15Asmalltrialoflisinoprilorlabetalolvsplacebosuggestedthatcasefatality(secondaryoutcome)wasreducedinpatientsreceiv-ingantihypertensivetherapy,althoughtherewasnoeffectonfunctionaloutcome(primaryoutcome).16Fewstudieshaveassessedtheeffectofantihypertensiveagentsoncerebralbloodflow(CBF),17althoughsomeagents,eg,nitrates,areabletolowerBPwithoutadverselyalteringcerebralbloodflow.18Nevertheless,allofthesestudiesenrolled 400patientsandnolargetrialshavebeencompletedinpatientswithacuteischemicstroke.

ThePreventionRegimenforEffectivelyAvoidingSecondStrokes(PRoFESS)trialisthelargestsecondarystrokepreventionstudyandcompared,inafactorialdesign,telmis-

ReceivedApril27,2009;finalrevisionreceivedJune24,2009;acceptedJuly20,2009.

FromtheStrokeTrialsUnit(P.M.W.B.),UniversityofNottingham,UK;DepartmentofBiostatistics,Bioinformatics,andEpidemiology(R.H.M.,Y.P.),MedicalUniversityofSouthCarolina,Columbia,SC;Biostatistics(D.C.),BoehringerIngelheimPharmaceuticals,Ridgefield,Conn;PopulationHealthResearchInstitute(S.Y.),McMasterUniversity,Hamilton,Canada;DivisionofNeurology(R.S.),UniversityofMiami,Miami,Fla;DepartmentofNeurology(H.-C.D.),UniversityDuisburg-Essen,Germany;EmergencyDepartmentStrokeUnit(D.T.),SapienzaUniversityofRome,Italy;NeurologicalCenter&ResearchUnit(C.E.),BuenosAires,Argentina;DepartmentofClinicalEpidemiology(R.R.),McMasterUniversity,Hamilton,Canada.

CorrespondencetoPhilipBath,StrokeTrialsUnit,UniversityofNottingham,CityHospitalcampus,NottinghamNG51PB,UK.E-mailphilip.bath@nottingham.ac.uk

©2009AmericanHeartAssociation,Inc.Strokeisavailableatdoc.guandang.net

DOI:10.1161/STROKEAHA.109.555623

第1页

你可能喜欢

热门文档

相关文档

站点地图 | 文档上传 | 侵权投诉 | 手机版
本站所有资源均来自互联网,本站只负责收集和整理,均不承担任何法律责任,如有侵权等其它行为请联系我们.
文档下载 Copyright 2013 doc.guandang.net All Rights Reserved.  -  email